Sabine Hojas

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

L. Pleyer, R. Greil, H. Döhner, 2017, International journal of molecular sciences.

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

L. Pleyer, R. Greil, S. Machherndl-Spandl, 2016, Journal of Hematology & Oncology.

Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?

L. Pleyer, R. Greil, S. Machherndl-Spandl, 2015 .

Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer

Qing Zhou, Ed Schuuring, Armin Gerger, 2020, ESMO Open.

Monitoring of minimal residual disease in patients with MLL–AF6‐positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction

O. Haas, U. Jäger, H. Greinix, 2000, British journal of haematology.

Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.

P. Regitnig, A. Porwit, G. Hoefler, 2014, Archives of pathology & laboratory medicine.

Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis

M. Fridrik, H. Gisslinger, H. Ludwig, 2013, Wiener klinische Wochenschrift.

Immunoquantification of lipoprotein(a): Comparison of nephelometry with electroimmunodiffusion

B. Tiran, A. Tiran, M. Wilders-Truschnig, 1993, Journal of clinical laboratory analysis.